In vivo evolution to echinocandin resistance and increasing clonal heterogeneity in Candida auris during a difficult-to-control hospital outbreak, Italy, 2019 to 2022-Reference-Cited by-同舟云学术

In vivo evolution to echinocandin resistance and increasing clonal heterogeneity in Candida auris during a difficult-to-control hospital outbreak, Italy, 2019 to 2022

Published:2023-04-06 Issue:14 Volume:28 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Codda Giulia¹,Willison Edward²,Magnasco Laura³,Morici Paola²,Giacobbe Daniele Roberto⁴³,Mencacci Antonella⁵⁶,Marini Daniele⁵⁶,Mikulska Malgorzata⁴³,Bassetti Matteo⁴³,Marchese Anna²¹,Di Pilato Vincenzo¹^ORCID

Affiliation:

1. Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy

2. Microbiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

3. Infectious Diseases Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

4. Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

5. Microbiology, Santa Maria della Misericordia Hospital, Perugia, Italy

6. Medical Microbiology, Department of Medicine, University of Perugia, Perugia, Italy

Abstract

A difficult-to-control outbreak of Candida auris is ongoing in a large tertiary care hospital in Liguria, Italy, where it first emerged in 2019. In a retrospective analysis, 503 cases of C. auris carriage or infection were observed between July 2019 and December 2022. Genomic surveillance identified putative cases that no longer occurred as part of one defined outbreak and the emergence of echinocandin (pandrug) resistance following independent selection of FKS1 S639F and FKS1 F635Y mutants upon prolonged exposure to caspofungin and/or anidulafungin.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference18 articles.

1. World Health Organization (WHO). WHO fungal priority pathogens list to guide research, development and public health action. Geneva: WHO; 2022. ISBN 978-92-4-006024-1. Available from: https://www.who.int/publications/i/item/9789240060241

2. Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021.;Kohlenberg;Euro Surveill,2022

3. Candida auris as an Emergent Public Health Problem: A Current Update on European Outbreaks and Cases.;Geremia;Healthcare (Basel),2023

4. Isolation of Candida auris from invasive and non-invasive samples of a patient suffering from vascular disease, Italy, July 2019.;Crea;Euro Surveill,2019

5. European Centre for Disease Prevention and Control (ECDC). Candida auris outbreak in healthcare facilities in northern Italy, 2019-2021. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-candida-auris-outbreak-healthcare-facilities-northern-italy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nosocomial transmission of fluconazole-resistant Candida glabrata bloodstream isolates revealed by whole-genome sequencing;Microbiology Spectrum;2024-08-20

2. Lower (1,3)-beta-d-glucan sensitivity and in vitro levels in Candida auris and Candida parapsilosis strains;Clinical Microbiology and Infection;2024-06

3. The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England;Journal of Medical Microbiology;2024-05-21

4. Potential Environmental Reservoirs of Candida auris: A Systematic Review;Journal of Fungi;2024-05-08

5. Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance;Journal of Clinical Microbiology;2024-04-10